Hubei Biocause Pharmaceutical Co., Ltd.

000627

CNE000000F48

Life & Health Insurance

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 23/05/2024 BST			5-day change	1st Jan Change
2.29 ^CNY	-2.55%		-6.91%	-19.37%

04-29	Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-15	Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Hubei Biocause Pharmaceutical Co., Ltd. cancelled the transaction announced on August 26, 2019

May 25, 2020

On May 26, 2020, Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) cancelled the transaction. The transaction has been approved in the 14th session of the company’s 8th directorate and the 12th session of the company’s 8th supervisory board.

Latest news about Hubei Biocause Pharmaceutical Co., Ltd.

Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-15	CI
Biocause Pharma’s Insurance Unit Posts Steady Annual Premium in 2023	01-15	MT
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10/23	CI
Hubei Biocause Pharmaceutical Co., Ltd. agreed to acquire 60% stake in Huarui Insurance Sales Co.,Ltd. for approximately CNY 150 million.	21/09/23	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	30/08/23	CI
Biocause Pharma Unit Logs 31 Million Yuan Insurance Premium Income in January-July Period	14/08/23	MT
Biocause Pharma Unit Generates 24 Billion Yuan Premium Income in January-May Period	12/06/23	MT
Hubei Biocause Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2022, Payable on 30 May 2023	22/05/23	CI
Biocause Pharma’s Life Insurance Unit Generates 22 Billion Yuan in January-April Premium Income	16/05/23	MT
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23	CI
Hubei Biocause Pharmaceutical Co., Ltd. Announces Final Profit Distribution Proposal for 2022	24/04/23	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	14/04/23	CI
Hubei Biocause Pharmaceutical Gets Regulatory Nod for Ibuprofen; Shares Down 5%	30/12/22	MT
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	28/10/22	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	29/08/22	CI
Biocause Heilen Pharma to Unlock 1.21% Restricted Stake	20/06/22	MT
Hubei Biocause Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021, Payable on June 2, 2022	24/05/22	CI
Hubei Biocause Pharmaceutical Co., Ltd. Proposes Cash Dividend for 2021	05/05/22	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	29/04/22	CI
Hubei Biocause’s Pharmaceutical Ingredients Unit Surges 64% in Shenzhen Debut	22/12/21	MT
Hubei Biocause’s Pharmaceutical Ingredients Unit Targets $243 Million in Shenzhen IPO	09/12/21	MT
Hubei Biocause’s Pharmaceutical Ingredients Unit Launches Shenzhen IPO	02/12/21	MT
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	29/10/21	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	30/08/21	CI

Chart Hubei Biocause Pharmaceutical Co., Ltd.

Duration

Period

Chart Hubei Biocause Pharmaceutical Co., Ltd.

More charts

Company Profile

Hubei Biocause Pharmaceutical Co.,Ltd. is a China-based company principally engaged in insurance business, such as life insurance, health insurance and casualty insurance. The Company is also involved in pharmaceutical business and chemical business. The Companyâs products include polypropylene and Ibuprofen. The Company distributes its products in domestic market and to overseas markets, with Central China and South China as its main markets.

Sector

Life & Health Insurance

Calendar

01/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Life & Health Insurance

	1st Jan change	Capi.
HUBEI BIOCAUSE PHARMACEUTICAL CO., LTD.	-19.37%	1.56B
AXA	+13.94%	80.24B
METLIFE, INC.	+9.69%	51.58B
AFLAC INCORPORATED	+6.29%	49.83B
MANULIFE FINANCIAL CORPORATION	+24.01%	47.73B
PRUDENTIAL FINANCIAL, INC.	+15.09%	42.86B
SUN LIFE FINANCIAL INC.	+1.50%	29.67B
GREAT-WEST LIFECO INC.	-2.71%	29.14B
PRUDENTIAL PLC	-13.68%	26.75B
CATHAY FINANCIAL HOLDING CO., LTD.	+20.00%	24.99B

Other Life & Health Insurance